Shares of Intersect ENT (NASDAQ:XENT) were unchanged at $13.49 after the company reported Q1 results.Quarterly Results Earnings per share decreased 54.29% year over year to ($0.54), which missed the estimate of ($0.44).Revenue of $19,826,000 lower by 25.67% year over year, which missed the estimate of $23,660,000.Guidance Earnings guidance hasn't been issued by the company for now.Intersect ENT hasn't issued any revenue guidance for the time being.Conference Call Details Date: May 11, 2020View more earnings on XENTTime: 07:04 PM ETWebcast URL: https://78449.choruscall.com/dataconf/productusers/xent/mediaframe/37432/indexr.htmlPrice Action 52-week high: $31.46Company's 52-week low was at $5.97Price action over last quarter: down 42.84%Company Description Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.See more from Benzinga * 13 Industrials Stocks Moving In Monday's Pre-Market Session * 15 Healthcare Stocks Moving In Monday's Pre-Market Session * 9 Consumer Cyclical Stocks Moving In Monday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Intersect ENT Reports First Quarter 2020 Results

Intersect ENT Announces Preliminary Revenue for First Quarter 2020 and Provides Business Update in Response to COVID-19 Pandemic

Intersect ENT Announces $65 Million Convertible Notes Investment from Deerfield Management

Specifically, a class action lawsuit was filed in federal court earlier this year against the Company on behalf of purchasers of the securities of Intersect from August 1, 2018 and May 6, 2019 (the "Class Period"). Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia.

Intersect ENT (XENT) delivered earnings and revenue surprises of -20.00% and 0.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Joining me today is Tom West, president and CEO of Intersect ENT. Before we begin, I would like to remind you that we will be making forward-looking statements within the meaning of the federal securities laws. Actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of those risks and uncertainties, which include, without limitation, our outlook for financial performance, sales force growth, clinical studies, approval of new products and indications and procurement of reimbursement codes and coverage, which are based upon our current estimates and assumptions, as well as other risk details from time to time in the reports we file with the SEC.

Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intersect ENT, Inc. (XENT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

Intersect ENT to Report First Quarter 2020 Financial Results

Intersect ENT to Present at the William Blair 40th Annual Growth Stock Conference

Intersect ENT (XENT) registers dull Propel performance on poor unit sales in Q4.

Investors who take an interest in Intersect ENT, Inc. (NASDAQ:XENT) should definitely note that the Executive VP...

Intersect ENT (XENT) performs disappointingly in the first quarter of 2020 due to the coronavirus crisis.

Specifically, a class action lawsuit was filed in federal court last year against the Company on behalf of purchasers of the securities of Intersect from August 1, 2018 and May 6, 2019 (the "Class Period"). According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Intersect lacked adequate reimbursement representatives to ensure physicians had access to SINUVA, Intersect's sinus implant; (2) Intersect's sales force would focus on ensuring reimbursement; (3) Intersect's sales representatives were less focused on driving sales; (4) physicians were less likely to adopt Intersect's SINUVA due to transaction costs associated with seeking reimbursement; (5) Intersect would increase staffing to address these issues; and (6) as a result of the foregoing, defendants' positive statements about Intersect's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Intersect ENT to Present at the 2020 Bank of America Merrill Lynch Global Healthcare Conference

Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intersect ENT Reschedules Time of First Quarter 2020 Financial Results Conference Call to 4:30 P.M. ET on May 11, 2020

Intersect (XENT) expects the impact of the coronavirus pandemic to substantially dampen revenues in the second quarter as well.